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A B S T R A C T   
The latent viral reservoir formed by HIV-1, mainly in CD4 + T cells, is responsible for the failure of antiretroviral 
therapy (ART) to achieve a complete elimination of the virus in infected individuals. We previously determined 
that CD4 + T cells from individuals with chronic myeloid leukemia (CML) on treatment with dasatinib are 
resistant to HIV-1 infection ex vivo. The main mechanism for this antiviral effect is the preservation of SAMHD1 
activity. In this study, we aimed to evaluate the impact of dasatinib on the viral reservoir of HIV-infected in-
dividuals with CML who were on simultaneous treatment with ART and dasatinib. Due to the low estimated 
incidence of HIV-1 infection and CML (1:65,000), three male individuals were recruited in Spain and Germany. 
These individuals had been on treatment with standard ART and dasatinib for median 1.3 years (IQR 
1.3–5.3 years). Reservoir size and composition in PBMCs from these individuals was analyzed in comparison with 
HIV-infected individuals on triple ART regimen and undetectable viremia. The frequency of latently infected cells 
was reduced more than 5-fold in these individuals. The reactivation of proviruses from these cells was reduced 
more than 4-fold and, upon activation, SAMHD1 phosphorylation was reduced 40-fold. Plasma levels of the 
homeostatic cytokine IL-7 and CD4 effector subpopulations TEM and TEMRA in peripheral blood were also 
reduced. Therefore, treatment of HIV-infected individuals with dasatinib as adjuvant of ART could disturb the 
reservoir reactivation and reseeding, which might have a beneficial impact to reduce its size.   
1. Introduction 
Infection by human immunodeficiency type 1 (HIV-1) is currently 
incurable despite the use of antiretroviral treatment (ART) due to long- 
lived, highly stable viral reservoir [1–3], mainly formed by a pool of 
latently infected CD4 + T cell. This reservoir shows variable size among 
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HIV-infected individuals, although it remains relatively stable over time, 
even in the presence of ART. It has been estimated to be formed by 106- 
107 latently infected CD4 + T lymphocytes [3,4] that may reactivate 
once ART is discontinued, causing viral rebound [5]. Viral rebound 
usually occurs within 2 weeks after ART discontinuation, reaching 
similar levels to acute infection [6,7]. Some individuals who initiated 
ART very early after infection and had extremely reduced reservoirs may 
control the residual viral load even after treatment discontinuation 
[8–13]. They are referred to as post-treatment controllers and the 
mechanism for this control may involve the HLA-B*35 allele [12] 
although additional unknown factors are likely to be important as well. 
Other individuals may exert a long-term control of the infection in which 
viremia remains undetectable in the absence of ART, as occurs for elite 
controllers [14–16] and long-term non-progressors (LTNP) [17–19]. 
This control of residual latently infected cells would mostly rely on the 
combination of an effective antiviral immune response with low reser-
voir size. Therefore, strategies aimed at reducing the size of the reservoir 
as much as possible, such as early initiation of ART, are essential toward 
gaining control of viral replication once ART is discontinued, paving the 
road for a potential HIV remission or a functional cure [20,21]. 
Although early ART influences the reservoir size and preserves CD4 
counts and consequently, the integrity of the immune response, it cannot 
completely circumvent the establishment of the reservoir, which occurs 
very early after the infection [22,23]. The extreme longevity of the 
latent reservoir has been attributed to the long half-life of the latently 
infected cells, which has been estimated in 3.7 years [1,24,25]. 
Accordingly, more than 70 years of ART would be necessary to eliminate 
the reservoir and eradicate the infection or at least, to reduce the 
reservoir size to a number of cells that could be controlled by the im-
mune response [26]. This long stability is also due to a continuous in-
crease of the latently infected cells mostly by homeostatic proliferation 
[27] and clonal expansion [28]. 
Our group described previously that tyrosine kinase inhibitors (TKIs) 
used for the treatment of chronic myeloid leukemia (CML) such as 
dasatinib [29,30] may have an important antiviral activity against HIV- 
1 replication [31]. This cytostatic drug interferes with TCR-mediated 
CD4 + T cell activation and therefore, impedes the integration and 
reactivation of HIV-1 provirus [32]. Moreover, dasatinib preserves the 
antiviral function of SAMHD1 by impeding its phosphorylation at T592, 
which is crucial for the restriction of HIV-1 replication in CD4 + T cells 
[33]. Finally, dasatinib blocks CD4 + T cell proliferation induced by 
homeostatic cytokines such as IL-2 and IL-7 [34] that are crucial for the 
stability of the viral reservoir [35]. The worldwide incidence of CML 
is<1 per 100,000 people [36] and CML is not commonly associated with 
HIV-1 [37]. The CML incidence on HIV-infected individuals is estimated 
to be 1:65,000 and therefore, few cases have been reported so far 
[37–48]. No information about the effect of TKIs on the progression of 
the viral reservoir has been reported to date but it could be essential to 
evaluate the pertinence of a clinical trial with dasatinib as adjuvant of 
ART in HIV-infected individuals. 
In this study, the effect of dasatinib on the size, composition and 
reactivation of the reservoir was analyzed in individuals infected with 
HIV-1 who afterwards developed CML. Individuals on simultaneous 
treatment with ART and dasatinib showed a small reservoir size as well 
as a resistance to proviral reactivation in infected peripheral CD4 + T 
cells. These findings provide supportive evidence to the emerging idea 
that treatment with dasatinib as an adjuvant to ART may contribute to a 
welcome smaller frequency of latently infected cells. 
2. Materials and methods 
2.1. Participants 
Blood samples were obtained from 3 individuals with chronic HIV-1 
infection who developed CML and were on treatment with ART and 
dasatinib, 32 individuals with chronic HIV-1 infection on treatment with 
ART, and 18 individuals with CML on treatment with dasatinib 
(Table 1). Eight healthy donors with similar age and gender distribution 
were recruited as controls. PBMCs were isolated by centrifugation 
through Ficoll-Hypaque gradient (Pharmacia Corporation, North Pea-
pack, NJ). CD4 + T cells were isolated by direct magnetic labeling using 
Human CD4 MicroBeads (Miltenyi, Bergisch Gladbach, Germany). 
Plasma and cells were cryopreserved until the moment of analysis. All 
relevant clinical data from individuals with chronic HIV-1 infection 
and/or CML are summarized in Table 2. 
2.2. Study approval 
All individuals gave informed written consent to participate. Confi-
dentiality and anonymity were protected by current Spanish and Euro-
pean Data Protection Acts. This study was performed in accordance with 
the Helsinki Declaration and it was previously approved by the Ethic 
Committee of Instituto de Salud Carlos III (IRB IORG0006384), ac-
cording to protocol with reference CEI PI 46_2018, and by the Ethics 
Committees of all participating hospitals. 
2.3. Quantification of proviral integration 
Whole genomic nucleic acid was extracted using QIAamp DNA Blood 
Mini Kit (Qiagen Iberia, Madrid, Spain). Proviral integrated DNA was 
quantified with TaqMan probes conjugated with FAM using a nested 
Alu-LTR PCR in a QuantStudio 3D Digital PCR System (Thermo Fisher 
Scientific España, Madrid, Spain), as previously described [49,50] with 
modifications. Briefly, a first conventional PCR was performed using 
oligonucleotides against Alu sequence and HIV-1 LTR, with the 
following conditions: 95 ◦C, 8 min; 12 cycles: 95 ◦C, 1 min; 60 ◦C, 1 min; 
72 ◦C, 10 min; 1 cycle: 72 ◦C, 15 min. Then, a second dPCR was 
Table 1 







Individuals, n 3 32 18 
Male/female, n 3/0 25/7 7/11 
Median age at HIV 
diagnosis (years) 
33.0 
(IQR 25.0 to 37.0) 
32.0 
(IQR 26.5 to 
39.0) 
N/A 
Median age at CML 
diagnosis (years) 
42.0 
(IQR 37.0 to 58.0) 
N/A 52.0 





(IQR 0.11 to 1.6) 
0.9 
(IQR 0.5 to 1.2) 
N/A 
Median CD4 count 
(cells/milliliter) 
786.0 
(IQR 178 to 1014) 
906 




2 NRTI, 1 INI (2) 
1 INI, 1 PI/c (1) 
1/2 NRTI, 1 
INI±c (14) 
1/2 NRTI, 1 
PI±c (6) 
2 NRTI, 1 INI/ 
c, 1 PI (1) 
2 NRTI, 1 
NNRTI (10) 
1 PI/c (1) 
N/A 
Sokal Risk Score, n 
(L/I/H/UD)** 
0/1/0/2 N/A 11/4/3/0 
Response at 
sampling***, n 
CCyR N/A 3 
MMR N/A 3 
DMR N/A 2 
*NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: Non-nucleoside 
reverse transcriptase inhibitor; PI: protease inhibitors; INI: integrase inhibitor; 
c: Cobicistat. 
** L, Low; I, Intermediate; H, High; UD, undetermined. 
*** CCyR, Complete Cytogenetic Response; MMR, Major Molecular Response; 
DMR, Deep Molecular Response. 
N/A: Not applicable. 
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Table 2 

































ART 1 M 40 N/A 618.8 840.1 1.2 3TC/ 
ABC/ 
DTG 
N/A N/A N/A N/A 
2 M 40 N/A 252.2 346.5 0.4 3TC/ 
ABC/ 
DTG 
N/A N/A N/A N/A 
3 M UD N/A UD 793.0 0.5 BIC/ 
FTC/ 
TAF 
N/A N/A N/A N/A 
4 M 39 N/A 123.1 UD UD BIC/ 
FTC/ 
TAF 
N/A N/A N/A N/A 
5 M 47 N/A 534.6 815.1 1.5 BIC/ 
FTC/ 
TAF 
N/A N/A N/A N/A 
6 M 42 N/A 722.5 UD 0.5 3TC/ 
DTG 
N/A N/A N/A N/A 
7 M UD N/A 142.8 458.5 0.5 DRV/c N/A N/A N/A N/A 
8 M 15 N/A 478.2 1097.4 1.0 BIC/ 
FTC/ 
TAF 
N/A N/A N/A N/A 
9 M 25 N/A 388.0 1250.0 UD EVG/ 
FTC/ 
TDF/c 
N/A N/A N/A N/A 
10 M 22 N/A 313.0 1108.0 UD EVG/ 
FTC/ 
TDF/c 
N/A N/A N/A N/A 
11 M 47 N/A 530.0 1462.0 UD 3TC/ 
ABC/ 
RPV 
N/A N/A N/A N/A 




N/A N/A N/A N/A 
13 M 31 N/A 292.0 763.0 UD EFV/ 
FTC/ 
TDF 
N/A N/A N/A N/A 
14 F 24 N/A UD 979.2 UD EVG/ 
FTC/ 
TDF/c 
N/A N/A N/A N/A 
15 F 32 N/A 91.0 969.0 UD FTC/ 
LOP/r 
N/A N/A N/A N/A 
16 F 37 N/A 283.0 1240.0 1.2 3TC/ 
ABC/ 
NVP 
N/A N/A N/A N/A 
17 M 27 N/A 90.0 832.0 1.3 DRV/ 
FTC/ 
TDF/c 
N/A N/A N/A N/A 
18 M 32 N/A 144.0 669.0 0.9 EVG/ 
FTC/ 
TAF/c 
N/A N/A N/A N/A 
19 F 29 N/A 167.0 1098.0 1.5 3TC/ 
ABC/ 
NVP 
N/A N/A N/A N/A 
20 M 31 N/A UD 892.0 1.1 3TC/ 
ABC/ 
DTG 
N/A N/A N/A N/A 
21 M 43 N/A 510.0 920.0 1.1 3TC/ 
ABC/ 
NVP 
N/A N/A N/A N/A 
22 F 37 N/A 363.0 2134.0 2.4 3TC/ 
ABC/ 
DTG 
N/A N/A N/A N/A 
23 M 35 N/A 521.0 1081.0 0.4 FTC/ 
RPV/ 
TDF 
N/A N/A N/A N/A 
24 M 38 N/A UD 1380.0 0.6 3TC/ 
ABC/ 
DRV/c 
N/A N/A N/A N/A 
25 F 22 N/A UD 579.0 0.4 N/A N/A N/A N/A 
(continued on next page) 
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performed using PrimeTime FAM/ZEN/Iowa Black TaqMan probes 
(Integrated DNA Technologies, Leuven, Belgium) and QuantStudio 
Digital PCR Chip kit (Applied Biosystems, Waltham, MA). CCR5 gene 
was used as housekeeping gene for measuring the input DNA and 
normalize data. Therefore, it was quantified in the same chip using 
TaqMan™ Gene Expression Assay and a VIC-conjugated Taqman probe 
(Thermo Fisher Scientific). QuantStudio 3D AnalysisSuite Cloud Soft-
ware was used for analysis (Thermo Fisher Scientific), based on the 
Poisson-Plus model that showed improved accuracy in the quantifica-
tion of results of digital PCR experiments [51]. 
2.4. Flow cytometry analysis 
Conjugated antibodies for surface staining CD3-APC and CD4-PercP 
were purchased from BD Biosciences (San Jose, CA). CD4 + T cell sub-
populations were analyzed by staining with CCR7-FITC and CD45RA- 
PE-Cy7 (BD Biosciences) as follows: naïve (TN) (CD45RA + CCR7 + ), 
central memory (TCM) (CD45RA-CCR7 + ), effector memory (TEM) 
(CD45RA-CCR7-) and terminally differentiated effector memory 
(TEMRA) (CD45RA + CCR7-) cells [52]. Antibodies for intracellular 
staining of HIV-1 core antigens (55, 39, 33 and 24 kDa proteins) (clone 




































26 M 23 N/A 268.0 609.0 0.7 3TC/ 
ABC/ 
DTG 
N/A N/A N/A N/A 
27 M 36 N/A 490.0 1099.0 1.2 EFV/ 
FTC/ 
TDF 
N/A N/A N/A N/A 
28 M 28 N/A 245.0 484.0 UD DRV/ 
FTC/ 
TAF/c 
N/A N/A N/A N/A 
29 F 31 N/A UD 1368.0 UD 3TC/ 
ABC/ 
ATV 
N/A N/A N/A N/A 
30 M 39 N/A 209.0 1225.6 UD 3TC/ 
ABC/ 
RPV 
N/A N/A N/A N/A 
31 M 37 N/A 349.0 540.0 UD EVG/ 
FTC/ 
TDF/c 
N/A N/A N/A N/A 
32 M 31 N/A 258.0 518.0 UD FTC/ 
RPV/ 
TDF 
N/A N/A N/A N/A 
ART þ dasatinib 33 M 33 37 563.0 1014.0 1.6 BIC/ 
FTC/ 
TAF 
UD 5 Imatinib 15 
34 M 37 58 <200.0 786.0 0.3 BIC/ 
FTC/ 
TAF 
High 3 N 16 
35 M 25 42 77.0 178.0 0.11 DTG/ 
DRV/c 
Interm. 4.5 Imatinib 63 
Dasatinib 36 F N/A 49 N/A N/A N/A N/A Low 4 Imatinib 30 




38 M N/A 55 N/A N/A N/A N/A Low 3 Imatinib. 
bosutinib 
30 




40 M N/A 24 N/A N/A N/A N/A Low 3 N 84 
41 F N/A 57 N/A N/A N/A N/A Interm. 3 Nilotinib 35 
42 F N/A 59 N/A N/A N/A N/A Low 4 N 30 
43 F N/A 57 N/A N/A N/A N/A Low 3 Imatinib 72 
44 M N/A 39 N/A N/A N/A N/A High N Nilotinib 1 
45 F N/A 56 N/A N/A N/A N/A High 5 N 48 
46 F N/A 55 N/A N/A N/A N/A High 5 N 4.5 
47 M N/A 43 N/A N/A N/A N/A Low 4.5 N 12 
48 M N/A 44 N/A N/A N/A N/A Interm. 4.5 Imatinib 84 
49 F N/A 60 N/A N/A N/A N/A Interm. 5 N 12 
50 F N/A 43 N/A N/A N/A N/A Low 5 Imatinib. 
nilotinib 
42 
51 F N/A 59 N/A N/A N/A N/A Interm. 5 Dasatinib 12 
52 M N/A 72 N/A N/A N/A N/A Low 4 N 48 
53 M N/A 26 N/A N/A N/A N/A Low 5 N 80 
ART, antiretroviral treatment; F, female; Interm., intermediate; M, male; N, no; N/A, non-applicable; TKI, tyrosine kinase inhibitor; U, undetected; UD, undetermined; 
Y, yes. 
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kc57) conjugated to FITC and SAMHD1 phosphorylated at Thr592 
(pSAMHD1) conjugated with PE were purchased from Beckman Coulter 
(Beckman Coulter Spain, Barcelona, Spain) and Cell Signaling (Cell 
Signaling Technology Europe, Leiden, The Netherlands), respectively. 
Data acquisition was performed in a BD LSRFortessa X-20 flow cytom-
eter using FACS Diva software (BD Biosciences). Data analysis was 
performed with FlowJo_V10 software (TreeStar, Ashland, OR). 
2.5. Proviral reactivation analysis 
CD4 + T cells isolated from HIV-infected individuals on ART were 
incubated ex vivo with Dynabeads human T activator CD3/CD28 
(Thermo Fisher Scientific) and 300 U/ml IL-2 (Chiron, Emeryville, CA) 
for 7 days, in the presence or absence of dasatinib 75 nM (37.9 ng/ml) 
(Selleckchem, Deltaclon, Madrid, Spain). CD4 + T cells isolated from 
individuals with HIV infection and CML were incubated ex vivo only 
with Dynabeads human T activator CD3/CD28 and IL-2 for 7 days and 
then with phorbol 12-myristate 13-acetate (PMA) 25 ng/ml and ion-
omycin 1.5 μg/ml for 18 h in the presence of brefeldin A (BD GolgiPlug, 
BD Biosciences). After fixation and permeabilization with IntraPrep 
Permeabilization Reagent (Beckman Coulter Spain), cells were stained 
with an antibody against HIV-1 core antigen (clone kc57) conjugated 
with FITC and an antibody against pSAMHD1. Phosphorylation of 
SAMHD1, which correlates with loss of its ability to restrict HIV-1 
replication [33], and the synthesis of HIV-1 core proteins were 
analyzed by flow cytometry, as described above. 
2.6. Intact proviral DNA assay (IPDA) 
The proportion of intact proviruses was evaluated in total DNA 
extracted from PBMCs of HIV-infected individuals treated only with ART 
or with ART and dasatinib. Two replicate wells of up to 1 µg DNA each 
were combined with ddPCR Supermix for Residual DNA Quantification 
(Bio-Rad, Bio-Rad Laboratories, Madrid, Spain) and multiplex prime/ 
probe sets targeting the packaging signal and envelope non- 
hypermutated sequences, as previously described [53]. Normalization 
by cell number and DNA shearing was based on quantifications in 
duplicate wells, containing 50 ng DNA each using a multiplex ddPCR 
targeting two regions of the RPP30 gene [54] and ddPCR Supermix for 
Probes (no dUTPs, Bio-Rad). All probes were FAM/HEX-ZEN- 
IowaBlackFQ double-quenched and purchased from Integrated DNA 
Technologies. Both quantifications were run simultaneously with the 
following thermal cycling conditions: 10 min at 95 ◦C followed by 45 
cycles consisting of 30 s at 94 ◦C; 60 s at 53 ◦C per cycle; final extension 
of 10 min at 98 ◦C and a final hold at 10 ◦C. Droplets were read on a 
QX100 Droplet Reader (Bio-Rad). 
2.7. Luminex assay 
A customized Human Magnetic Luminex Assay kit (R&D Systems) 
was used for the simultaneous detection of homeostatic cytokines in 
plasma: IL-2, IL-7, IL-15, and IL-21. Instructions provided by the supplier 
were followed and analysis was performed on a Bio-Plex 200 System 
(Bio-Rad). 
2.8. Statistical analysis 
Statistical analysis was performed using Graph Pad Prism 9.0 (Graph 
Pad Software Inc., San Diego, CA). Statistical significance among groups 
was calculated using one-way ANOVA and Tukey’s multiple compari-
sons test. Statistical differences among two populations were calculated 
with Mann–Whitney non-parametric U test. P values (p) < 0.05 were 
considered statistically significant in all comparisons and were repre-
sented as *, **, or *** for p < 0.05, p < 0.01 and p < 0.001, respectively. 
3. Results 
3.1. Individuals’ characteristics 
This is an observational, cross-sectional study in which participated a 
total of 59 individuals divided in 4 cohorts. 
Three individuals infected with HIV-1 who were diagnosed after-
wards with CML were recruited at ICH Study Center (Hamburg, Ger-
many) (Participant 33), the University Hospital of Cologne (Cologne, 
Germany) (Participant 34), and Hospital Universitario Severo Ochoa 
(Madrid, Spain) (Participant 35) (Tables 1 and 2). 
Participant 33 is a 47-year old Caucasian male who was diagnosed 
with HIV-1 infection when he was 33-year old and with CML when he 
was 37-year old. He had been on treatment with raltegravir, abacavir 
and lamivudine for 9 years which was later simplified to bictegravir, 
emtricitabine and tenofovir (BIC/FTC/TAF). His HIV-RNA was unde-
tectable (<50 copies/mL) more than 9 years. He had also been on 
imatinib for 9 years that was changed for dasatinib due to some intol-
erability (fatigue, polyneuropathy). At the time of last sampling, he had 
been on treatment with dasatinib for 1 year and 3 months, CD4 count 
was 1014 cells/μl and CD4/CD8 ratio was 1.6. He maintained CML 
molecular response of 4.0 (ratio BCR-ABL1/ABL1 ≤ 0.01%) and unde-
tectable viral load. 
Participant 34 is a 59-year old Caucasian male who was diagnosed 
with HIV-1 infection when he was 37-year old and with CML when he 
was 58-year old (1 year and 4 months ago). He was on treatment with 
zidovudine, rilpivirine and tenofovir (AZT/RPV + TDF) at CML diag-
nosis and initiated bictegravir, emtricitabine and tenofovir (BIC/FTC/ 
TAF) after introducing dasatinib 15 months ago to avoid interactions. 
No other TKI was administered prior to dasatinib. At the time of last 
sampling, CD4 count was 786 cells/μl, CD4/CD8 ratio was 0.3 and he 
showed CML molecular response 3.0 (ratio BCR-ABL1/ABL1 ≤ 0.1%) 
and undetectable viral load. 
Participant 35 is a 52-year old Caucasian male who was diagnosed 
with HIV-1 infection when he was 25-year old and with CML when he 
was 42-year old (first described in Campillo-Recio et al. [38]). He was on 
treatment with dolutegravir and darunavir/cobicistat (DTG/DRC/c) and 
with imatinib for 4 years. Due to poor adherence to both treatments, he 
experienced recurrent rebounds of plasma viremia, low CD4 count (178 
CD4/μl; CD4/CD8 ratio 0.11) and failure to imatinib treatment. As a 
consequence, dasatinib was introduced and he had been on treatment 
with it for 5 years and 3 months when the first blood sample was taken. 
Due to pneumonia, he discontinued treatment with dasatinib for 
5 months and then nilotinib was introduced. He maintained CML mo-
lecular response of 4.5–5.0 (ratio BCR-ABL1/ABL1 ≤ 0.0032%) since 
then (2 years). He showed undetectable viral load at the time of 
sampling. 
Thirty-two individuals with chronic HIV-1 infection on ART and 
undetectable viral load were also recruited for this study (Table 1) and 
were followed up for 1 year. They were selected according to their age, 
gender and ART regimen to match the individuals with HIV infection 
and CML. Median time on ART was similar between HIV-infected in-
dividuals treated only with ART and those on ART and dasatinib. Most 
individuals were male (78%), their median age at HIV-1 diagnose was 
32 years (interquartile range (IQR) 27 to 39) and their median age at 
sampling was 44 years (IQR 37 to 54). Most ART regimens (43.75%) 
consisted of one or two nucleoside reverse transcriptase inhibitors 
(NRTIs) and one integrase inhibitor (INI) with or without cobicistat. 
Median CD4 count was 906 cells/μl (IQR 601.5 to 1137.4) and median 
CD4/CD8 ratio was 0.9 (IQR 0.5 to 1.2). Table 2 shows relevant clinical 
data of these individuals. Due to the limited number of cells isolated per 
sample, not all the analyses were performed with all the samples. 
Eighteen individuals diagnosed with chronic phase CML were also 
recruited for this study (Table 1). They were all on treatment with 
dasatinib and on hematological and cytogenic remission. Most in-
dividuals were female (61%) and their median age at diagnosis of CML 
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was 52.0 years (IQR 40.5 to 57.5). Sixty-one percent showed low 
prognostic Sokal risk and 66.7% presented deep molecular response 
against cancerous cells at the time of sampling (ratio BCR-ABL1/ 
ABL1 ≤ 0.0032%). Median time of treatment with dasatinib was 
2.5 years (interquartile range (IQR) 0.5 to 4.0). Table 2 shows relevant 
clinical characteristics of these individuals. 
Eight healthy donors with similar age and gender distribution were 
recruited as negative controls. 
3.2. Quantification of HIV-1 proviral integration 
The frequency of HIV-1 infected cells was quantified by dPCR in 
individuals on treatment only with ART or with ART and dasatinib. The 
treatment time with ART was similar in both groups of individuals. 
Proviral integration was 5.7-fold lower on average in individuals treated 
with dasatinib (p < 0.05) (Fig. 1a). A two-year followup of participants 
on treatment with ART and dasatinib was performed in order to analyze 
changes in the proviral DNA. No significant changes were found be-
tween samples (Fig. 1b). 
3.3. Effect of dasatinib on provirus reactivation 
In order to determine whether the presence of dasatinib was inter-
fering with the in vitro reactivation of the provirus from the reservoir of 
HIV-infected individuals, CD4 + T cells isolated from PBMCs of these 
individuals were activated for 7 days with aCD3/CD28/IL-2 in the 
presence (+) or absence (-) of dasatinib in the culture medium. 
Reactivation of the provirus was induced by treatment with PMA and 
ionomycin for 18 h in the presence of brefeldin A to prevent the release 
of viral proteins to the culture medium. CD4 purity was determined as 
98%. Previous in vitro treatment with dasatinib reduced 4.4-fold on 
average the production of HIV-1 core antigens from the viral reservoir 
(p < 0.01) (Fig. 2a). SAMHD1 phosphorylation was reduced more than 
30-fold on average (p < 0.01) in CD4 + T cells when dasatinib was added 
to the culture medium before the activating stimuli (Fig. 2b). 
The effect of dasatinib in vivo on the proviral reactivation was 
analyzed in CD4 + T cells isolated from PBMCs of HIV + CML in-
dividuals on ART and dasatinib, and then compared to proviral reac-
tivation from CD4 + T cells isolated from HIV-infected individuals only 
on ART. The production of HIV-1 core antigens from the viral reservoir 
was reduced 7.3-fold on average (p < 0.01) in CD4 + T cells from in-
dividuals treated with ART and dasatinib (Fig. 2c). Treatment in vivo 
with dasatinib also dramatically impaired SAMHD1 phosphorylation of 
CD4 + T cells, as it was reduced more than 21-fold on average in in-
dividuals on ART and dasatinib (p < 0.01) (Fig. 2d). 
3.4. Quantification of intact proviruses 
We previously described a potent cytostatic effect of dasatinib on 
CD4 + T cells that cannot be overcome by TCR-mediated stimuli or 
cytokine-induced homeostatic activation [32,34]. However, the possi-
bility that dasatinib was also interfering with the fitness of the pro-
viruses in the reservoir should be investigated. Therefore, the proportion 
of intact proviruses was evaluated by IPDA in individuals 33 and 34 in 
Fig. 1. Treatment with ART and dasatinib reduced the frequency of latently infected cells. (A) Quantification by dPCR of proviral DNA per million of PBMCs from 
HIV-infected individuals on treatment with ART (participants 33, 34 and 35) and dasatinib in comparison with individuals only on ART. (B) Followup of the 
previously indicated participants, highlighting the sample represented in the previous bar graph for participants 33, 34 and 35 (black triangle) or individuals on 
treatment only with ART (black circle). Each dot corresponds to one sample and lines represent mean ± standard error of the mean (SEM). Statistical significance was 
calculated using Mann–Whitney U test. *p < 0.05. 
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comparison with those individuals only on ART who presented similar 
levels of total integrated provirus (as shown in Fig. 1a). This analysis was 
not performed in participant 35 due to scarcity of the sample. No dif-
ferences were found between the proportions of intact proviruses in the 
reservoir of individuals treated with ART and dasatinib in comparison 
with individuals only treated with ART and similar reservoir size 
(Fig. 3a). The levels of hypermutated 3′-deleted and 5′-deleted pro-
viruses were slightly increased in participant 33 who had been on 
Fig. 2. Treatment with dasatinib interfered efficiently with 
TCR-mediated reactivation of HIV-1 provirus. The synthesis of 
HIV-1 core antigens (A) and the phosphorylation of SAMHD1 
(B) were quantified by flow cytometry in CD4 + T cells isolated 
from PBMCs of HIV-infected individuals only on ART activated 
for 7 days with antiCD3/CD28/IL-2 in the presence (+) or 
absence (-) of dasatinib in the culture medium. The synthesis of 
HIV-1 core antigens (C) and the phosphorylation of SAMHD1 
(D) were also quantified by flow cytometry in CD4 + T cells 
isolated from PBMCs of HIV-infected individuals on treatment 
only with ART or with ART and dasatinib (Participants 33, 34 
and 35), activated for 7 days with antiCD3/CD28/IL-2. Each 
dot corresponds to one sample and lines represent 
mean ± SEM. Open symbols stand for undetected values. Sta-
tistical significance was calculated using Mann–Whitney U test. 
** p < 0.01.   
Fig. 3. Treatment with dasatinib did not change significantly the proportion of intact and defective HIV-1 proviruses in PBMCs from individuals 33 and 34. The 
proportion of intact proviruses (A), hypermutated/3′-deleted (B) and 5′-deleted (C) proviruses per million of cells was evaluated by IPDA in PBMCs from individuals 
33 and 34 in comparison with HIV-infected individuals treated only with ART. Each dot corresponds to one sample and lines represent mean ± SEM. Open symbols 
stand for undetected values. Statistical significance was calculated using Mann–Whitney U test. 
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treatment with imatinib for more 9 years and then dasatinib for 
1.25 years, in comparison with participant 34 who had been on treat-
ment with dasatinib for 1.3 years (Fig. 3b and c). 
3.5. Distribution of CD4 + T cell subpopulations 
Total levels of CD3 + cells were not significantly affected by treat-
ment with dasatinib in HIV-infected individuals (Fig. 4a), but the level of 
CD4 + T cells was reduced 1.6-fold on average in individuals treated 
with dasatinib (p < 0.05) (Fig. 4b). This CD4 lymphopenia has been 
described previously during treatment with dasatinib, and accordingly, 
we observed the same low CD4 levels in CML individuals treated with 
dasatinib (p < 0.01). Despite the reduction in CD4 + T cell levels, 
CD3 + cells were increased in individuals with CML in comparison with 
HIV-infected individuals (p < 0.05) (Fig. 4a). 
Treatment with dasatinib increased the proportion of CD4 + TCM 
2.5-fold on average in HIV-infected individuals on ART and dasatinib, in 
comparison with individuals only treated with ART (p < 0.01) (Fig. 4c). 
Conversely, the levels of effector CD4 + TEMRA cell subpopulation were 
overall reduced 3.3-fold on average in these individuals. CD4 + T naïve 
(TN) cells were also reduced 2.5-fold. 
3.6. Effect of dasatinib on plasma levels of homeostatic cytokines 
HIV-infected individuals on treatment with ART and dasatinib 
showed levels of IL-7 that were reduced 2.3-fold in comparison with 
individuals only on ART (Fig. 5a). Plasma levels of IL-21 and IL-15 were 
reduced 1.7- and 1.6-fold, respectively (Fig. 5b and c), whereas IL-2 
levels remained unchanged (Fig. 5d) in both groups of individuals. 
4. Discussion 
The latent reservoir is very dynamic in HIV-infected individuals on 
ART and the rate of decay for intact provirus is more rapid than defective 
provirus [55]. Therefore, more than 88% of the proviruses that form the 
reservoir are supposed to be defective [56]. However, the presence of 
intact proviruses, even in a very low proportion, is enough to produce 
the rebound of viremia in the absence of ART [57,58]. 
HIV-infected individuals who develop CML and are on ART and TKIs 
constitute a special cohort of individuals with a very low reservoir size. 
The viral reservoir in participant 33, who had been on treatment with 
imatinib for 9 years and with dasatinib for 1.25 years, showed unde-
tectable intact proviruses and higher levels of defective proviruses than 
participant 34 who had been on treatment with dasatinib as first-line for 
1.3 years. During the follow-up, the frequency of latently infected cells 
in participant 34 decreased to very low levels after 5 months of treat-
ment with dasatinib, whereas the reservoir size in participant 35 
increased 1 year after changing dasatinib for nitotinib. Therefore, long- 
term treatment with TKIs seemed to have a positive effect on the 
reservoir size, being the combination of imatinib and dasatinib the one 
Fig. 4. Treatment with dasatinib modified the distribution of CD4 + T cell subpopulations in HIV-infected individuals. The proportion of CD3+ (A) and CD4+ (B) 
cells in PBMCs from HIV-infected individuals treated only with ART or treated with ART and dasatinib (individuals 33, 34 and 35) was compared to individuals HIV 
negative affected with CML on treatment only with dasatinib and with healthy donors. (C) The distribution of CD4 + T cell subpopulations was determined by flow 
cytometry in PBMCs isolated from these three groups of individuals after staining with antibodies against CCR7 and CD45RA. Each dot corresponds to one sample and 
lines represent mean ± SEM. Statistical significance was calculated using One-way ANOVA. * p < 0.05; ** p < 0.01. 
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that showed better results. Due to the presence of intact proviruses in 
participant 34, the reactivation of the provirus upon TCR-mediated 
activation should be possible at least in PBMCs from this individual. 
However, although the latent reservoir in PBMCs from individuals on 
treatment with ART and TKIs was detectable, it could not be reactivated 
in vitro in response to potent TCR-mediated activation. Most likely, this 
was due to the potent cytostatic activity of dasatinib, as was reflected in 
the low level of SAMHD1 phosphorylation and the impaired activation 
of essential transcription factors such as NF-ΚB [32]. This long-term 
effect of dasatinib on the inhibition of SAMHD1 phosphorylation in 
CD4 + T cells was previously described in individuals with CML on 
chronic treatment with this TKI [59]. The preservation of SAMHD1 
antiviral function probably contributes to the protective activity of TKIs 
against HIV-1 infection, which is supported by the extremely low fre-
quency of latently infected cells in the cohort of HIV-infected individuals 
with CML. 
Other mechanisms are probably involved in the effect of dasatinib on 
the smaller size of HIV-1 reservoir in these individuals. We previously 
described that CD4 + T cells from individuals treated with dasatinib are 
unresponsive to homeostatic cytokines such as IL-7 [34]. This interfer-
ence with CD4 proliferation did not affect the viability of the cells, but 
due to the potent antiproliferative effect, it could interfere with the 
reservoir replenishment and consequently, contribute to the decrease of 
the reservoir size. Moreover, treatment with dasatinib showed a ten-
dency to reduce the levels of IL-7 in vivo in individuals on ART and 
dasatinib, although without statistical significance maybe due to data 
dispersion. It is noteworthy that participant 33 showed the smallest level 
of IL-7 in correlation with undetectable levels of intact provirus. Dasa-
tinib also affects the distribution of CD4 + T cell subpopulations [60]. 
Although highly stable CD4 + TCM cells are considered the main 
component of the reservoir [27], the largest contributors to HIV-1 
reservoir maintenance are the effector memory CD4 + T cells, such as 
TEM and TEMRA [61]. Individuals on ART and dasatinib showed lower 
levels of CD4 + TEMRA cells that are short-lived, express high levels of 
Fig. 5. Treatment with dasatinib changed the levels of ho-
meostatic cytokines in plasma of HIV-infected individuals. 
Plasma levels of IL-7 (A), IL-21 (B), IL-15 (C) and IL-2 (D) from 
HIV-infected individuals on ART and dasatinib (Participants 
33, 34 and 35) or only with ART were analyzed by Luminex 
assay and compared to plasma levels of HIV negative in-
dividuals with CML on treatment with dasatinib and healthy 
donors. Each dot corresponds to one sample and lines represent 
mean ± SEM. Statistical significance was calculated using 
Mann–Whitney U test.   
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activation markers [62] and contain a higher quantity of unstable viral 
forms [63], thereby contributing more efficiently to the proviral 
rebound and reservoir replenishment. Besides, CD4 + TN cells, which 
are considered an important contributor to the latent reservoir [64,65] 
and have remarkably long half-lives (1–8 years) [66], were also greatly 
reduced in individuals on ART and dasatinib. As a consequence, the 
proportion of TCM was increased in comparison with individuals only 
on ART. This different distribution of CD4 + T cell subpopulations may 
suggest a restricted dynamism of the viral reservoir in the presence of 
dasatinib. 
An important limitation of this study, apart from the low incidence of 
HIV-1 infection and CML that makes very unlikely the recruitment of 
more individuals with both diseases, is that although CD4 + T cells are 
the most important reservoir of HIV-1 infection, they are not the only 
one. Therefore, more analyses are necessary to evaluate the effect of 
ART and dasatinib not only in blood CD4 + T cells but also in other cell 
types that form part of the reservoir such as macrophages and in other 
anatomic sanctuaries such as the gut-associated lymphoid tissue (GALT) 
and the lymph nodes [67]. These sanctuaries may be highly stable due to 
the inaccessibility for efficient drug distribution, which may be 
responsible for low drug concentration and low-level replication [68]. 
However, the apparent volume of distribution of dasatinib has been 
estimated as 2,505 L, suggesting that it is extensively distributed in the 
extravascular space [69]. 
On the other hand, in vitro and ex vivo studies suggest that lower 
concentrations of dasatinib than the dose usually used to treat CML may 
be able to develop an efficient antiviral effect [70]. The dose of dasatinib 
used ex vivo was 75 nM (38 ng/ml) which correlates with Cmax reached 
in healthy adults after the administration of 50 mg once per day [71], 
although the recommended dose of dasatinib is 100 mg per day [69]. We 
previously demonstrated that the lowest dose of dasatinib that was 
effective as antiviral is 16 nM (8.26 ng/ml) [32], which means that one- 
ninth of the recommended dose for the treatment of CML can be used to 
be adjuvant of ART. We also demonstrated that treatment with dasatinib 
ex vivo was very safe, with a selectivity index higher than 600 [32], 
which ruled out the possibility that the absence of proviral reactivation 
in CD4 + T cells from HIV-1 infected individuals was due to an increased 
cytotoxicity due to treatment ex vivo. Consequently, the main side ef-
fects attributed to dasatinib, which are mainly cytopenia, pleural effu-
sion and infectious complications [69], would probably be infrequent 
with low doses administered during short periods of time [60,70]. 
Nevertheless, these potential adverse effects should be carefully moni-
tored during simultaneous administration of ART and dasatinib due to 
dasatinib is mostly metabolized by cytochrome P450 3A4 (CYP3A4) 
[69,72] and therefore, potential interactions with some ART regimens 
should be avoided [70]. In particular, ART regimens containing CYP3A4 
inhibitors such as ritonavir or cobicistat should not be used simulta-
neously with dasatinib to avoid a potential increase in adverse effects 
[73]. Conversely, CYP3A4 inducers such as non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), mostly efavirenz, etravirine, and ne-
virapine [74], would reduce the antiviral effect of dasatinib when 
administered simultaneously. However, no interactions are expected 
with current recommended regimens including nucleoside reverse 
transcriptase inhibitors (NRTIs) or integrase strand transfer inhibitors 
(INSTIs) such as raltegravir or dolutegravir. 
In summary, the low frequency of latently infected cells observed in 
individuals on ART and dasatinib may be due to several mechanisms: 
first, the preservation of SAMHD1 antiviral activity exerted by dasatinib 
that would prevent the infection of new target cells; second, the 
blockage of reservoir replenishment by homeostatic proliferation 
mediated by IL-7; third, the potent cytostatic effect of dasatinib on 
CD4 + T cells that would prevent their activation and the subsequent 
reactivation of the latent provirus; and finally, changes in the distribu-
tion of CD4 + T cell subpopulations that would reduce the levels of 
effector CD4 + T cells with the ability to reseed the reservoir. 
In conclusion, treatment with TKIs such as dasatinib as adjuvant of 
ART could be considered a potential therapeutic intervention to reduce 
the size of HIV-1 reservoir and its reactivation from latency. So far, 
allogeneic hematopoietic stem cell transplant (HSCT) in HIV-infected 
people with hematological malignancies has been the only clinical 
intervention that has efficiently reduced the reservoir size [75]. Unfor-
tunately, this approach is not scalable to all people living with HIV. 
Although short-term treatment with dasatinib might not likely cause so 
dramatic reduction of the frequency of latently infected cells as HSCT, 
the intervention would be safer and may be applied to a wider popula-
tion of HIV-infected individuals. Accordingly, treatment with ART and 
low-dose dasatinib might have a beneficial impact on the reservoir size 
to help control the reactivation of residual latently infected CD4 + T 
cells after ART discontinuation, hopefully improving the possibilities for 
a functional cure in chronically HIV-1 infected individuals. Our data 
support the conduct of a pilot clinical trial to test this hypothesis. 
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